ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

NEW YORK, March 31, 2024

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's October 21, 2021 initial public offering (the "IPO" or "Offering"); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period"), of the important April 30, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Ventyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Offering Documents and defendants made false and/or misleading statements and/or failed to disclose that: (1) VTX958, Ventyx's lead clinical product candidate for psoriasis, psoriatic arthritis, and Crohn's disease, was less effective in treating psoriasis than defendants had led investors to believe; (2) as a result, VTX958's clinical and/or commercial prospects were overstated; (3) accordingly, Ventyx had misrepresented its ability to develop and commercialize effective product candidates; (4) Ventyx's post-IPO business prospects were thus inflated; and (5) as a result, Ventyx's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.